Aug 2026· Virchows Archiv· 0 citations· 53 references
Medicine
TL;DR
Screening tumor types for which a first-line, integrated DNA-RNA NGS strategy provides a valuable advantage for rapid therapeutic decisions demonstrates that integrated DNA-RNA high-throughput NGS enables timely, precise molecular profiling for personalized therapy in solid tumors.
Routine targeted NGS provides detailed molecular characterisation of CRC and generates information relevant to biomarker-informed clinical decision-making in real-world practice, however, targeted panels alone were insufficient to establish robust molecular subgroups in this retrospective cohort.
Afonso Cunha, C. Robalo, C. Lemos et al.· International Journal of Mol...· 0 citations
The clinical utility and acceptable TAT of a comprehensive WES and RNA-seq assay for LBCL managed in routine clinical practice are demonstrated and support the real-world feasibility of using integrated WES and RNA-seq to define molecular subgroups, guide clinical decision-making at the time of a new line of therapy, a...
Dai Chihara, Kumudha Balakrishnan, G. Masand et al.· Blood Advances· 0 citations
Re-evaluation of molecular profiles using ctDNA enabled the exploratory identification of NeoRAS wild-type patients, who could potentially benefit from anti-EGFR therapy, in a real-world setting.
K. Ito, K. Kataoka, Yoshiko Muroi et al.· Journal of the Anus Rectum a...· 0 citations
Evaluating the diagnostic and clinical impact of molecular profiling in pediatric soft tissue sarcomas using the Oncomine Childhood Cancer Research Assay (OCCRA) panel demonstrates that comprehensive molecular profiling significantly enhances diagnostic accuracy in pediatric soft tissue sarcomas, particularly in morpho...
F. Tesser-Gamba, T. B. Mendes, Fernanda Teresa de Lima et al.· International Journal of Mol...· 0 citations
This study evaluated the amplicon-based NGS Plasma-SeqSensei™ Solid Cancer In Vitro Diagnostics (IVD) Kit (Sysmex) against the real-time PCR-based cobas® EGFR Mutation Test v2 (Roche), the current routine standard at the Veneto Institute of Oncology IOV-IRCCS, finding it to be a robust and highly sensitive assay.
Andrea Boscolo Bragadin, Valeria Tosello, S. Longo et al.· Diagnostics· 0 citations
Two PDOs with differential responses to carboplatin derived from sequential ascites fluid collections from a patient with high-grade müllerian carcinoma are described and the ability of long-read sequencing to add detail into the genomics and epigenetics of ovarian cancer is demonstrated.
J. Wendt, Kristin M. Adams, Ryan Moreno et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.